Study of ABI-6250 for chronic hepatitis D
Part of Infections clinical trials.
This trial tests a new medicine called ABI-6250 for people with chronic hepatitis D. It aims to see if the drug is safe and helps control the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis D (and hepatitis B).
- Your body mass index (BMI) is between 18 and 35.
- You are generally healthy apart from hepatitis B and D.
- You have not had treatment for hepatitis D in the last 6 months.
- You are willing to use effective contraception if needed.
- You do not have other active infections like hepatitis A, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
This study tests a new medicine called Hepalatide for people with chronic hepatitis D, a serious liver infection. It aims to see if the drug can reduce the virus and improve liver health. You may be eligible if you have both hepatitis B and D and are on stable hepatitis B treatment.
This study tests an experimental medicine called ABI-6250 in people with mild liver problems compared to healthy people. It aims to see how the drug affects the body and if it is safe.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
Hear when a new Chronic Hepatitis D Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.